Singapore-based clinical-stage biotechnology company Lion TCR has announced the successful completion of its Series B2 financing round, raising RMB 300 million (USD 42 million). The investment was led by Guangzhou Industrial Investment and Capital, Guoju Venture Capital, and CSPC Pharmaceutical Group. The funds will be allocated towards advancing clinical studies, constructing a GMP compliant facility, and expanding the company’s pipeline.
Investment to Accelerate Clinical Development and Infrastructure
The proceeds from the Series B2 financing will play a crucial role in Lion TCR’s ongoing clinical studies, which are essential for the development of new therapies. Additionally, the funds will be used to construct a facility that complies with Good Manufacturing Practice (GMP) standards, ensuring that the company’s products meet the highest quality and safety standards.
Lion TCR’s Innovative Cell Therapy Platforms and Pipeline
Lion TCR has established a robust pipeline with a focus on toll cell receptor (TCR)-focused discovery and RNA technology platforms. The company is developing both autologous and allogeneic cell therapy programs, demonstrating its commitment to innovation in the field of cellular therapies. Lion TCR’s product pipeline includes treatments for hepatocellular carcinoma (HCC) and chronic hepatitis B virus (HBV), addressing significant unmet medical needs.
Expanding the Horizons in Cell Therapy
With the completion of this financing round, Lion TCR is well-positioned to expand its pipeline and strengthen its presence in the cell therapy space. The investment will not only support the company’s immediate clinical and infrastructure needs but also contribute to the long-term development of potentially life-saving therapies.-Fineline Info & Tech
